Actively Recruiting
Observational Registry of OssDsign Bone Graft Substitutes in Spine Fusion Surgery Collecting Real-World Clinical Outcomes and Safety Data
Led by OssDsign · Updated on 2026-10-28
450
Participants Needed
16
Research Sites
1 weeks
Total Duration
AI-Summary
What This Trial Is About
This research aims to collect information on the clinical outcomes and real-world use of OssDsign bone graft substitutes in patients who require spine fusion surgery. The study is a multi-center, prospective, observational registry involving up to 25 sites in the US. It focuses on patients diagnosed with degenerative disc disease or spinal stenosis who undergo spine fusion with OssDsign bone grafts. Participants receive commercially available OssDsign Catalyst bone graft substitutes, which are osteoconductive, resorbable, porous, and made of 100% nano synthetic calcium phosphate. The study will follow patients for up to 24 months 90 days after their index spine fusion surgery where the bone graft was implanted. The primary outcome measured is the rate of bone fusion approximately 12 months after surgery. During the study, participants will undergo clinical and radiographic follow-up evaluations including quality of life questionnaires such as the Oswestry Disability Index, Neck Disability Index, Visual Analog Scale, and Short Form 36 at multiple time points up to 24 months. Neurological function and presence of bone fusion will also be assessed at 6, 12, and 24 months. Safety reviews of device-related adverse events will be conducted throughout the study period.
CONDITIONS
Brief Title
OssDsign® Spine Registry Study ("Propel")
Research Team
J
jeff Feldhaus
A
Anne McKibbin
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here